| Acute Leukemia |
1 |
1 |
| Biologic Therapy |
0 |
0.99 |
| Stem Cell Research and Therapy |
0 |
0.93 |
| CAR-T |
0 |
0.85 |
| Transplantation |
0 |
0.43 |
| Cell Transplantation |
0 |
0.36 |
| Adverse Effects |
0 |
0.29 |
| Chemotherapy |
0 |
0.29 |
| Refractory |
0 |
0.29 |
| Patient Safety |
0 |
0.27 |
| Toxicology |
0 |
0.21 |
| Leukemia |
0 |
0.16 |
| Pediatric Oncology |
0 |
0.15 |
| Cancer |
0 |
0.14 |
| Child |
0 |
0.14 |
| Remission |
0 |
0.14 |
| Pediatric Transplantation |
0 |
0.13 |
| Acute Lymphoblastic Leukemia |
0 |
0.1 |
| Antigens |
0 |
0.07 |
| Canada |
0 |
0.07 |
| Immunotherapy |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Texas |
0 |
0.07 |
| Young Adult |
0 |
0.07 |